Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Prolight Diagnostics ABLTS:0G5I 31 EV-to-FCF is -2.87 as of Aug. 02, 2026. GuruFocus rates LTS:0G5I with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 417 Medical Devices & Instruments companies, Prolight Diagnostics AB ranks worse than 239807.91% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Prolight Diagnostics AB's Enterprise Value is kr198.34 Mil.
Prolight Diagnostics AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr-69.07 Mil. Therefore, Prolight Diagnostics AB's EV-to-FCF for today is -2.87.
The historical rank and industry rank for Prolight Diagnostics AB's EV-to-FCF or its related term are showing as below:
LTS:0G5I'
s EV-to-FCF Range Over the Past 10 Years
Min: -3.01 Med: 0 Max: 0
Current: -3.01
LTS:0G5I's EV-to-FCF is ranked worse than 100% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 23.52
vs LTS:0G5I: -3.01
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prolight Diagnostics AB (LTS:0G5I) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Prolight Diagnostics AB's PE Ratio (TTM) for today is calculated as:
Prolight Diagnostics AB's share price for today is kr15.70.
Prolight Diagnostics AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-4.870.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Prolight Diagnostics AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prolight Diagnostics AB EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Prolight Diagnostics AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Prolight Diagnostics AB's EV-to-FCF falls into.
Prolight Diagnostics AB's current Enterprise Value is kr198.34 Mil.
Prolight Diagnostics AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-69.07 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prolight Diagnostics AB (LTS:0G5I) has a EV-to-FCF of -2.87 as of Aug. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Prolight Diagnostics AB and its competitors. According to the industry distribution chart, Prolight Diagnostics AB ranks #999999 out of 417 companies in the Medical Devices & Instruments industry.
Is Prolight Diagnostics AB's EV-to-FCF too high?
Prolight Diagnostics AB's current EV-to-FCF is -2.87. Based on the distribution chart, Prolight Diagnostics AB ranks #999999 out of 417 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Prolight Diagnostics AB has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Prolight Diagnostics AB's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Prolight Diagnostics AB ranks #999999 out of 417 companies for EV-to-FCF. This places Prolight Diagnostics AB in the lower half of its industry. The industry median EV-to-FCF is 23.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.52, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Prolight Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prolight Diagnostics AB's current EV-to-FCF is -2.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prolight Diagnostics AB stock overvalued right now?
Prolight Diagnostics AB (LTS:0G5I) has a current EV-to-FCF of -2.87. The current EV-to-FCF is -2.87. Prolight Diagnostics AB's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Prolight Diagnostics AB (LTS:0G5I), the current EV-to-FCF is -2.87 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prolight Diagnostics AB along with its subsidiaries, develops Point-of-Care (POC) systems, which are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. Its product portfolio includes Psyros, a digital POC technology, and Microflex.
31GF Score
Get the complete analysis for LTS:0G5I
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0G5I has been successfully added to your 
